Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
NCT06422247 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 307
Last updated 2025-06-04
Summary
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
Conditions
- Peripheral T-cell Lymphoma
Interventions
- DRUG
-
Systemic therapy
Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-05
- Primary Completion
- 2025-02-05
- Completion
- 2025-02-05
- FDA Drug
- Yes
Countries
- Japan
More Related Trials
-
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
NCT04317066 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas
NCT02597153 ·Status: TERMINATED ·Phase: PHASE2
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
NCT01142674 ·Status: COMPLETED
-
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
NCT02221492 ·Status: COMPLETED ·Phase: PHASE2
-
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
NCT02927964 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
NCT03703375 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
NCT02929615 ·Status: UNKNOWN ·Phase: PHASE4
-
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
NCT06712173 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997 ·Status: UNKNOWN
-
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
NCT06940791 ·Status: RECRUITING ·Phase: PHASE2
-
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT07093710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT07139353 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
NCT02342665 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
NCT05137847 ·Status: COMPLETED
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT02169180 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
NCT03927105 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
NCT05400876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
NCT03316144 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
NCT03021057 ·Status: UNKNOWN ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004874 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2